Funder: ALS Association
Due Dates: September 23, 2025 (Letter of Intent) | January 13, 2026 (Full application)
Funding Amounts: Up to $12 million in direct costs per project; up to 5 years duration; total program up to $60 million.
Summary: Funds rigorous, patient-centered comparative effectiveness research to improve care, symptom management, and diagnosis for rare diseases.
Key Information: Requires robust patient/stakeholder engagement and is not for new technology development or methods-only research.